Roche/Antisoma Ovarian Cancer Agent Phase III Failure Will Likely End Development
This article was originally published in The Pink Sheet Daily
Executive Summary
Radio-linked monoclonal antibody R-1549 did not meet primary endpoint of survival for ovarian cancer in pivotal SMART trial. Three additional cancer agents licensed by Roche under collaboration with Antisoma are in Phase I.